{"id":43145,"date":"2022-03-12T11:26:51","date_gmt":"2022-03-12T16:26:51","guid":{"rendered":"https:\/\/sciencebusiness.technewslit.com\/?p=43145"},"modified":"2022-03-12T11:27:58","modified_gmt":"2022-03-12T16:27:58","slug":"infographic-corp-venture-funding-leaps-in-2021","status":"publish","type":"post","link":"https:\/\/technewslit.com\/sciencebusiness\/?p=43145","title":{"rendered":"Infographic – Corp. Venture Funding Leaps in 2021"},"content":{"rendered":"
\"Chart:<\/a>
Click on image for full-size view (CB Insights)<\/figcaption><\/figure>\n

12 Mar. 2022. Venture capital is a topic we report on often at Science & Enterprise, both individual finance deals and overall trends. One source of venture funds making a substantial presence last year is investment divisions of corporations, known as corporate venture capital or CVC. Earlier this month, technology market intelligence company CB Insights issued a report on the state of corporate venture capital<\/a> (registration required), which points out its growing impact.<\/p>\n

In 2021, according to CB Insights, total investments from CVCs reached $169.3 billion for the year, up from $70.1 billion in 2020. Total investment dollars stayed relatively stable from 2018 to 2020, but the 2021 total is a 141.5 percent increase from the previous year. The number of new venture investment deals by CVCs also jumped markedly last year to 221, a 52 percent increase from 2020, after a two-year decline.<\/p>\n

The CB Insights report also lists the most active CVCs in the last quarter of 2021, which includes two investor names familiar to regular readers of Science & Enterprise. The report says Google Ventures, known as GV, was the most active CVC in the fourth quarter supporting 27 companies. In July 2021 we reported on GV’s participation in the $200 million second round financing for Prime Medicine<\/a>, spun-off from the Broad Institute, that conducts precise base-pair genetic editing.<\/p>\n

Another of the most active CVCs is Alexandria Venture Investments, supporting 15 start-ups in Q4. Just this week, Science & Enterprise reported on $40 million in early funds for Creyon Bio<\/a>, a new company designing RNA components on demand for therapeutics, with Alexandria Venture Investments taking part in that round.<\/p>\n

More from Science & Enterprise:<\/p>\n